Please assess the completion status of the following clinical trial:

Trial Title: An Efficacy and Safety Study of Desloratadine (MK-4117) in Japanese Participants With Chronic Urticaria (MK-4117-201)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Chronic urticaria \[rash (erythema, wheal) for more than 1 month without any known cause\]~* Out-patient~Exclusion Criteria:~* Stimulation-induced urticaria \[physical urticaria (e.g. cold, solar, and heat urticaria), cholinergic urticaria, contact urticaria)\]~* Hypersensitivity to antihistamines or ingredients of a study drug

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Desloratadine 5 mg (Type: EXPERIMENTAL): Participants receive desloratadine 5 mg, as one 5-mg tablet and one placebo tablet, orally, once daily in the evening for 2 weeks
- Desloratadine 10 mg (Type: EXPERIMENTAL): Participants receive desloratadine 10 mg, as two 5-mg tablets, orally, once daily in the evening for 2 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Participants receive placebo, as two tablets, orally, once daily in the evening for 2 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).